Evidence map›Paper›PMID 40329122›Full record

SynthesisInternational journal of clinical oncology2025

Efficacy and safety of cancer vaccine therapy in malignant melanoma: a systematic review.

Takeshi Seta, Shohei Nakamura, Mitsuaki Oura, Kazuki Yokoyama, Yoshitaka Nishikawa, Nobuaki Hoshino, Kiichiro Ninomiya, Tatsunori Shimoi, Katsuyuki Hotta, Takeo Nakayama

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Takeshi SetaDepartment of Gastroenterology and Hepatology and Gastrointestinal Cancer Center, JRC Wakayama Medical Center, 4-20, Komatsubara-Dori, Wakayama City, Wakayama, 640-8558, Japan.ORCID http://orcid.org/0000-0002-3057-6284
Shohei NakamuraDepartment of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-Ku, Tokyo, 113-8677, Japan.ORCID http://orcid.org/0009-0001-2855-721X
Mitsuaki OuraDepartment of Hematology and Oncology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.ORCID http://orcid.org/0000-0002-4907-4647
Kazuki YokoyamaDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.ORCID http://orcid.org/0009-0003-5730-1066
Yoshitaka NishikawaDepartment of Health Informatics, Kyoto University School of Public Health, Yoshidakonoe-Cho, Sakyo-Ku, Kyoto, 606-8501, Japan.ORCID http://orcid.org/0000-0003-3313-1990
Nobuaki HoshinoDepartment of Surgery, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507, Japan.ORCID http://orcid.org/0000-0002-7171-8971
Kiichiro NinomiyaCenter for Comprehensive Genomic Medicine, Okayama University Hospital, 2-5-1 Kitaka-Cho, Kita-Ku, Okayama, 700-8558, Japan.ORCID http://orcid.org/0000-0002-2134-2865
Tatsunori ShimoiDepartment of Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan. tshimoi@ncc.go.jp.ORCID http://orcid.org/0000-0002-3603-8575
Katsuyuki HottaCenter for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.ORCID http://orcid.org/0000-0002-0112-0843
Takeo NakayamaDepartment of Health Informatics, Kyoto University School of Public Health, Yoshidakonoe-Cho, Sakyo-Ku, Kyoto, 606-8501, Japan.ORCID http://orcid.org/0000-0002-7918-6252

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMalignant melanoma is a cancer that develops from melanocytes in the skin and mucous membranes. Surgery, and chemotherapy, radiation therapy, or immunotherapy are also used in cases of distant metastasis. Immunotherapy includes immune checkpoint inhibitors and cancer vaccine therapy; however, their efficacy remains limited.

methodsA systematic review and meta-analysis of cancer vaccine therapies were conducted. PubMed was used to search the literature up to December 2023, and clinical trials were also identified for the same period. RCTs involving patients with resectable or unresectable malignant melanoma were included. The primary outcome was OS, and secondary outcomes were PFS, DFS, and RFS. Safety was assessed based on AEs. Integrated results were presented as risk ratio and risk difference.

resultsThe initial search identified 418 studies on cancer vaccine therapy and 44 studies on effector T-cell therapy. We supplemented this with our PubMed search, extracting 149 studies. After database searches and screening, 611 studies were initially considered. Following exclusions based on eligibility criteria, 20 RCTs using cancer vaccines remained. For the primary outcome, OS, the pooled RR was 1.11 (95% CI, 0.97-1.32, I

conclusionCancer vaccine therapy, neither alone, or in combination with other agents for malignant melanoma did not show a significant improvement in OS, PFS, DFS, or RFS nor did it significantly increase AEs.

Indexed as

Cancer VaccinesMelanomaSkin NeoplasmsCutaneous Malignant MelanomaHumansImmune Checkpoint InhibitorsRandomized Controlled Trials as TopicCancer VaccinesImmune Checkpoint InhibitorsAntitumor effectMalignant melanomaSurvivalSystematic reviewVaccine therapy

Identifiers

PMID40329122

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.